Non-Proliferative Diabetic Retinopathy Global Market Report 2025

Description

Non-proliferative diabetic retinopathy (NPDR) stands as a prevalent complication of diabetes mellitus, impacting the retina-the light-sensitive tissue lining the rear of the eye. NPDR manifests through alterations in the retina's blood vessels due to prolonged exposure to elevated blood sugar levels (hyperglycemia) associated with diabetes. Its management involves a blend of medical interventions, lifestyle adjustments, and routine eye examinations aimed at halting disease progression and preserving vision.

The primary treatments for non-proliferative diabetic retinopathy encompass anti-vascular endothelial growth factor (VEGF) therapy, intraocular steroid injection, laser surgery, and vitrectomy. Anti-vascular endothelial growth factor (VEGF) therapy entails the administration of medications that impede vascular endothelial growth factor (VEGF) to deter abnormal blood vessel growth within the retina. This treatment is prescribed across varying severity levels, including mild, moderate, and severe non-proliferative diabetic retinopathy, and is typically administered in hospitals, specialized clinics, ambulatory surgical centers, and similar healthcare settings.

The non-proliferative diabetic retinopathy market research report is one of a series of new reports from The Business Research Company that provides non-proliferative diabetic retinopathy market statistics, including non-proliferative diabetic retinopathy industry global market size, regional shares, competitors with a non-proliferative diabetic retinopathy market share, detailed non-proliferative diabetic retinopathy market segments, market trends and opportunities, and any further data you may need to thrive in the non-proliferative diabetic retinopathy industry. This non-proliferative diabetic retinopathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-proliferative diabetic retinopathy market size has grown strongly in recent years. It will grow from $2.62 billion in 2024 to $2.84 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increased prevalence of diabetes, aging population, improved awareness, research advancements, lifestyle changes and improved diabetes management.

The non-proliferative diabetic retinopathy market size is expected to see strong growth in the next few years. It will grow to $3.87 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to adoption of telemedicine, development of novel therapeutics, integration of artificial intelligence, increasing investments in research and development, and expansion of healthcare infrastructure. Major trends in the forecast period include increasing adoption of artificial intelligence for screening and diagnosis, rising demand for telemedicine and remote monitoring solutions, emergence of, personalized medicine approaches for diabetic retinopathy treatment, growing focus on preventive strategies and early intervention, and expanding role of patient-centered care models in managing diabetic retinopathy.

The growing prevalence of diabetes is expected to drive the expansion of the non-proliferative diabetic retinopathy market in the coming years. Diabetes is a chronic metabolic condition characterized by elevated blood glucose levels due to insufficient insulin production by the pancreas or the body's cells becoming resistant to insulin. The condition is primarily caused by factors such as sedentary lifestyles, poor dietary habits, and genetic predispositions. Diabetes leads to non-proliferative diabetic retinopathy by damaging the blood vessels in the retina, mainly from prolonged exposure to high blood glucose levels, which results in impaired vision and potentially blindness. For example, in June 2024, the National Health Service (NHS), a UK-based government agency, reported that in 2023, over half a million (549,000) additional individuals in England were found to be at risk of developing type 2 diabetes. This brought the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330, a significant increase from 3,065,825 in 2022, representing nearly a 20% rise. Consequently, the increasing incidence of diabetes is fueling the growth of the non-proliferative diabetic retinopathy market.

Key players in the non-proliferative diabetic retinopathy market are focusing on developing AI-enabled cameras to enhance patient outcomes and revolutionize ophthalmic imaging. These cameras, equipped with artificial intelligence algorithms, aid in capturing, analyzing, and interpreting eye images for diagnostic and therapeutic purposes. For instance, in May 2024, Optomed, a Finland-based medical technology company, introduced Optomed Aurora AEYE, a handheld AI fundus camera designed to instantly detect diabetic retinopathy beyond mild stages. This innovative device combines portability with the power of artificial intelligence to deliver high-quality retinal images for early detection and monitoring of various eye conditions. The Optomed Aurora AEYE utilizes AI algorithms to assist healthcare professionals in analyzing retinal images, enabling swift and accurate diagnosis of conditions such as diabetic retinopathy, glaucoma, and age-related macular degeneration.

In January 2022, Meteda S.r.l., an Italy-based nutrition solutions company, acquired Retmarker SA to strengthen its position in providing innovative solutions for chronic diseases such as diabetes, particularly in diabetic retinopathy screening. This strategic move enhances Meteda's ability to address healthcare needs on a broader scale and prevent blindness among individuals with diabetes worldwide. Retmarker SA, a Portugal-based biotechnology company, specializes in developing medical devices serving as biomarkers for the progression of diabetic retinopathy.

Major companies operating in the non-proliferative diabetic retinopathy market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Abbott Laboratories, Novartis AG, Eli Lilly and Company, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Genentech Inc., Carl Zeiss Meditec AG, ZEISS Group, Santen Pharmaceutical Co. Ltd., Santen Inc., Topcon Corporation, Lumenis Ltd., Alimera Science, Ocular Therapeutix Inc., Acucela Inc., Ampio Pharmaceuticals, Kowa Company Ltd., Nidek Co. Ltd.

North America was the largest region in the non-proliferative diabetic retinopathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-proliferative diabetic retinopathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-proliferative diabetic retinopathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-proliferative diabetic retinopathy (NPDR) market consists of revenues earned by entities by providing services such as ophthalmological consultations, optometric services, contract research services, and counselling services. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-proliferative diabetic retinopathy (NPDR) market also includes sales of fundus cameras, optical coherence tomography (OCT) machines, laser photocoagulation equipment, and injections. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Proliferative Diabetic Retinopathy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-proliferative diabetic retinopathy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-proliferative diabetic retinopathy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-proliferative diabetic retinopathy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Treatment Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy; Intraocular Steroid Injection; Laser Surgery; Vitrectomy
2) By Disease Severity Level: Mild Non-Proliferative Diabetic Retinopathy; Moderate Non-Proliferative Diabetic Retinopathy; Severe Non-Proliferative Diabetic Retinopathy
3) By End-User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Other End-Users
Subsegments:
1) By Anti-Vascular Endothelial Growth Factor (Vegf) Therapy: Bevacizumab (Avastin); Ranibizumab (Lucentis); Aflibercept (Eylea); Pegaptanib (Macugen)
2) By Intraocular Steroid Injection: Triamcinolone Acetonide; Dexamethasone Implant (Ozurdex); Fluocinolone Acetonide Implant (Iluvien)
3) By Laser Surgery: Focal Laser Photocoagulation; Panretinal Photocoagulation
4) By Vitrectomy: Pars Plana Vitrectomy (Ppv); Membrane Peeling Vitrectomy; Phaco-Vitrectomy (Combined Cataract And Vitrectomy Surgery)
Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche AG; AbbVie Inc.; Bayer AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r30795

1. Executive Summary

2. Non-Proliferative Diabetic Retinopathy Market Characteristics

3. Non-Proliferative Diabetic Retinopathy Market Trends And Strategies

4. Non-Proliferative Diabetic Retinopathy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Non-Proliferative Diabetic Retinopathy Growth Analysis And Strategic Analysis Framework

5.1. Global Non-Proliferative Diabetic Retinopathy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Non-Proliferative Diabetic Retinopathy Market Growth Rate Analysis
5.4. Global Non-Proliferative Diabetic Retinopathy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Non-Proliferative Diabetic Retinopathy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Non-Proliferative Diabetic Retinopathy Total Addressable Market (TAM)

6. Non-Proliferative Diabetic Retinopathy Market Segmentation

6.1. Global Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Anti-Vascular Endothelial Growth Factor (VEGF) Therapy
Intraocular Steroid Injection
Laser Surgery
Vitrectomy
6.2. Global Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Mild Non-Proliferative Diabetic Retinopathy
Moderate Non-Proliferative Diabetic Retinopathy
Severe Non-Proliferative Diabetic Retinopathy
6.3. Global Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Ambulatory Surgical Centers
Other End-Users
6.4. Global Non-Proliferative Diabetic Retinopathy Market, Sub-Segmentation Of Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Bevacizumab (Avastin)
Ranibizumab (Lucentis)
Aflibercept (Eylea)
Pegaptanib (Macugen)
6.5. Global Non-Proliferative Diabetic Retinopathy Market, Sub-Segmentation Of Intraocular Steroid Injection, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Triamcinolone Acetonide
Dexamethasone Implant (Ozurdex)
Fluocinolone Acetonide Implant (Iluvien)
6.6. Global Non-Proliferative Diabetic Retinopathy Market, Sub-Segmentation Of Laser Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Focal Laser Photocoagulation
Panretinal Photocoagulation
6.7. Global Non-Proliferative Diabetic Retinopathy Market, Sub-Segmentation Of Vitrectomy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pars Plana Vitrectomy (PPV)
Membrane Peeling Vitrectomy
Phaco-Vitrectomy (Combined Cataract And Vitrectomy Surgery)

7. Non-Proliferative Diabetic Retinopathy Market Regional And Country Analysis

7.1. Global Non-Proliferative Diabetic Retinopathy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Non-Proliferative Diabetic Retinopathy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Non-Proliferative Diabetic Retinopathy Market

8.1. Asia-Pacific Non-Proliferative Diabetic Retinopathy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Non-Proliferative Diabetic Retinopathy Market

9.1. China Non-Proliferative Diabetic Retinopathy Market Overview
9.2. China Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Non-Proliferative Diabetic Retinopathy Market

10.1. India Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Non-Proliferative Diabetic Retinopathy Market

11.1. Japan Non-Proliferative Diabetic Retinopathy Market Overview
11.2. Japan Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Non-Proliferative Diabetic Retinopathy Market

12.1. Australia Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Non-Proliferative Diabetic Retinopathy Market

13.1. Indonesia Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Non-Proliferative Diabetic Retinopathy Market

14.1. South Korea Non-Proliferative Diabetic Retinopathy Market Overview
14.2. South Korea Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Non-Proliferative Diabetic Retinopathy Market

15.1. Western Europe Non-Proliferative Diabetic Retinopathy Market Overview
15.2. Western Europe Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Non-Proliferative Diabetic Retinopathy Market

16.1. UK Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Non-Proliferative Diabetic Retinopathy Market

17.1. Germany Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Non-Proliferative Diabetic Retinopathy Market

18.1. France Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Non-Proliferative Diabetic Retinopathy Market

19.1. Italy Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Non-Proliferative Diabetic Retinopathy Market

20.1. Spain Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Non-Proliferative Diabetic Retinopathy Market

21.1. Eastern Europe Non-Proliferative Diabetic Retinopathy Market Overview
21.2. Eastern Europe Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Non-Proliferative Diabetic Retinopathy Market

22.1. Russia Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Non-Proliferative Diabetic Retinopathy Market

23.1. North America Non-Proliferative Diabetic Retinopathy Market Overview
23.2. North America Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Non-Proliferative Diabetic Retinopathy Market

24.1. USA Non-Proliferative Diabetic Retinopathy Market Overview
24.2. USA Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Non-Proliferative Diabetic Retinopathy Market

25.1. Canada Non-Proliferative Diabetic Retinopathy Market Overview
25.2. Canada Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Non-Proliferative Diabetic Retinopathy Market

26.1. South America Non-Proliferative Diabetic Retinopathy Market Overview
26.2. South America Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Non-Proliferative Diabetic Retinopathy Market

27.1. Brazil Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Non-Proliferative Diabetic Retinopathy Market

28.1. Middle East Non-Proliferative Diabetic Retinopathy Market Overview
28.2. Middle East Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Non-Proliferative Diabetic Retinopathy Market

29.1. Africa Non-Proliferative Diabetic Retinopathy Market Overview
29.2. Africa Non-Proliferative Diabetic Retinopathy Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Non-Proliferative Diabetic Retinopathy Market, Segmentation By Disease Severity Level, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Non-Proliferative Diabetic Retinopathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Non-Proliferative Diabetic Retinopathy Market Competitive Landscape And Company Profiles

30.1. Non-Proliferative Diabetic Retinopathy Market Competitive Landscape
30.2. Non-Proliferative Diabetic Retinopathy Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Non-Proliferative Diabetic Retinopathy Market Other Major And Innovative Companies

31.1. Abbott Laboratories
31.2. Novartis AG
31.3. Eli Lilly and Company
31.4. Novo Nordisk A/S
31.5. Regeneron Pharmaceuticals Inc.
31.6. Bausch Health Companies Inc.
31.7. Boehringer Ingelheim International GmbH
31.8. Genentech Inc.
31.9. Carl Zeiss Meditec AG
31.10. ZEISS Group
31.11. Santen Pharmaceutical Co. Ltd.
31.12. Santen Inc.
31.13. Topcon Corporation
31.14. Lumenis Ltd.
31.15. Alimera Science

32. Global Non-Proliferative Diabetic Retinopathy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-Proliferative Diabetic Retinopathy Market

34. Recent Developments In The Non-Proliferative Diabetic Retinopathy Market

35. Non-Proliferative Diabetic Retinopathy Market High Potential Countries, Segments and Strategies

35.1 Non-Proliferative Diabetic Retinopathy Market In 2029 - Countries Offering Most New Opportunities
35.2 Non-Proliferative Diabetic Retinopathy Market In 2029 - Segments Offering Most New Opportunities
35.3 Non-Proliferative Diabetic Retinopathy Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer